AI Pharma Research in 2027: Choosing a First Use Case That Delivers Results

The hard part is choosing the use case

R&D teams in pharma are being asked to show results from AI, but the first question is rarely which model to buy. It is where to start. Literature reviews, target triage, trial design, protocol drafting, regulatory writing, and experimental data analysis all look compelling in a steering committee deck. When a team tries to pilot several of these at once, the outcome is usually a set of half-finished demos, reviewers with no time to check outputs, and no clean baseline to prove anything worked.

The real challenge is selection. You need a research workflow that is valuable enough to matter, bounded enough to finish, and safe enough to withstand scientific and regulatory scrutiny.

The main AI use cases in pharma R&D

Most AI activity in pharma R&D falls into a few recurring categories. Recognizing them helps teams avoid treating every idea as equally urgent.

The first category is information work: literature screening, patent landscape scans, summarizing internal study reports, and searching historical lab records. These tasks consume a significant share of scientists' time, and even when the content is complex, the structure of the work is repetitive.

The second category is analytical support, such as interpreting assay outputs, flagging anomalies in plate-level data, and organizing multi-omics results for review. Here AI typically assists the human analyst rather than replacing the analysis.

The third category is design and documentation work: drafting clinical protocol sections, comparing inclusion criteria against a library of past protocols, and preparing first drafts of regulatory narratives. The output is always a draft that requires expert and quality review.

The fourth category is operational research, including feasibility assessment for study sites, patient recruitment matching, and reconciling data from vendors or contract research organizations (CROs). The business value of these use cases is often high, but they depend heavily on the quality of operational data.

The last category is frontier discovery work, such as generative molecular design or predictive models for candidate screening. The upside is large, but validation depends on wet-lab experiments and long timelines, so returns are slow and difficult to attribute.

Ranking by value and difficulty

A useful way to rank options is to use two dimensions. Value covers how many expert hours the workflow consumes each week, how much the output would change a decision, and whether the same pattern recurs across multiple projects. Difficulty covers how clean and accessible the data is, how much validation the output needs, how much regulatory risk is involved, and how many systems must be integrated.

Plotting use cases on these two dimensions reveals a rough landscape. Literature and internal knowledge retrieval usually sit in the high-value, low-to-medium-difficulty zone, because the source material already exists and outputs can be checked against citations. Protocol and document drafting sits in the middle: valuable, but every sentence needs expert sign-off and version control. Operational matching tools can be very valuable but depend on data pipelines that many organizations have not yet cleaned up. Discovery and predictive modeling are the hardest, with the longest feedback loops.

This ranking is a starting point, not a verdict. If a team has well-structured, high-quality assay data, it may find that analytical support is easier to deploy than literature work. The key is to score every candidate use case on the same two dimensions so the selection is transparent rather than driven by enthusiasm. For a more complete method for scoring candidate use cases, see the guide: Enterprise AI Use Case Prioritization.

Why the obvious choice often fails

The most common mistake is starting with the most ambitious use case. A team wants to prove that AI can accelerate discovery, so it begins with generative chemistry. A few months later, it has plausible-looking candidate compounds that cannot be confirmed quickly, and the sponsors gradually lose confidence in the project.

The second mistake is treating outputs as conclusions. A model that summarizes twenty papers is useful only if a scientist checks each claim against the original sources. Without a review gate, errors move into steering committee decks and protocol documents.

The third mistake is ignoring data provenance. If the system pulls from documents with unclear versions, restricted sources, or uncontrolled copies, the pilot creates compliance problems while trying to solve a research problem.

The fourth mistake is running a pilot without a control. If nobody recorded how long literature reviews took before the tool was introduced, there is no way to tell whether the tool helped. Many pilots end up with only positive anecdotes and no basis for a decision.

How to select and set up the first pilot

A good first pilot meets five conditions. The question is bounded, for example "summarize prior studies on one target class and list conflicting findings," rather than "find new targets." The source material already exists in a reasonably organized form. A specific expert is willing to review outputs every week. The task has a measurable baseline, such as reviewer time per request or the number of days needed to produce a first draft. And the patient safety risk of the first version is low, with no direct path into regulatory submissions.

Under these conditions, internal literature and report retrieval is usually the most sensible first step. Researchers already understand the task, it is easy to evaluate, and it produces a clear before-and-after comparison: how long the work took before and after the tool, and how often reviewers had to correct the answers.

When setting up the pilot, first fix the corpus. Define which documents, databases, and internal reports the system may use, and exclude content with unclear ownership or uncontrolled versions. Require every answer to include specific source citations so reviewers can verify a claim in seconds rather than minutes.

Next, set a review gate. Every output used for a decision should be reviewed by a named scientist, who records corrections by type: wrong source, missing source, misread result, or claim without support. These correction records are among the most valuable data a pilot generates, because they show where the system needs tighter constraints.

Finally, check data readiness before scaling. Many research teams discover that their internal documents are scattered, duplicated, or inconsistently labeled. A short readiness review based on the Data Readiness Assessment Guide can keep the pilot from stalling in data cleanup.

If your team wants to run this kind of tightly scoped workflow end to end, a platform such as Duaer can bring bounded knowledge base setup, citation-based answers, and reviewer workflows into one place, so the pilot tests the research question rather than the technical pipeline. No platform replaces expert review, and results ultimately depend on your data quality and governance.

How to measure results, and one thing to do this week

Measure results against the pilot's own baseline, not against general enthusiasm for AI. Four metrics are usually enough. Per-task cycle time compares the hours or days needed for the same type of review before and after the tool. Correction rate tracks how often reviewers change the output, broken down by error type. Citation accuracy is measured by sampling: each week, reviewers check a fixed number of answers against their sources. Adoption tracks how many researchers use the tool repeatedly, not just during the demo.

Define success thresholds before the pilot begins. If the correction rate stays high after two review cycles, tighten the corpus or narrow the question scope. If accuracy is good but adoption is low, the problem is workflow fit, not the model. A pilot that gives a clear answer in either direction is more valuable than one that quietly drifts off target.

One thing you can do this week: list ten recurring research tasks your team completed in the past month, such as literature screening, study report summaries, or protocol section reviews. For each task, estimate the hours spent and the number of people involved, then score value and difficulty on the two dimensions described above. Choose the task with the highest value and lowest regulatory risk, and write down its current baseline in one sentence. That sentence is the starting point for your first pilot.

AI returns in pharma R&D come from applying it to a carefully chosen workflow, with reviewers, a clear baseline, and explicit decision rules. Start small, prove that your measurement is reliable, and expand only after the first use case has delivered value. If you want to test a tightly scoped research workflow on your own data, you can sign up for a Duaer trial and set up your first bounded pilot this month.